Nevirapin Ratiopharm (Nevirapine)

Nevirapine, the active ingredient in Nevirapin Ratiopharm, is a non‑nucleoside reverse transcriptase inhibitor (NNRTI) presented as an oral tablet for oral use. It is employed in the treatment of HIV‑1 infection as part of combination antiretroviral therapy in adults and adolescents.

GNH USA supplies Nevirapin Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards, offers batch‑tested products, and provides regulatory‑compliant sourcing for global healthcare providers. It maintains full compliance with EU GMP guidelines and supports reliable supply chains across continents.

Nevirapine is used in antiretroviral therapy targeting HIV‑1 replication.

- HIV‑1 infection: reduces viral load when combined with other antiretrovirals in treatment‑naïve patients. - Treatment‑experienced HIV‑1 infection: provides an alternative NNRTI option for patients with prior regimen failure. - Pediatric HIV‑1 infection (≥2 years): contributes to viral suppression as part of age‑appropriate combination therapy.

Nevirapine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Rash: mild to moderate skin eruptions. - Nausea: transient gastrointestinal discomfort. - Headache: mild to moderate intensity. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Hepatotoxicity: elevated liver enzymes or hepatitis, potentially leading to liver failure. - Severe hypersensitivity: fever, eosinophilia, and systemic symptoms. - Neutropenia: marked reduction in white blood cells increasing infection risk.

Before initiating therapy, clinicians should consider several safety measures.

- Liver function monitoring: assess baseline transaminases and repeat during therapy. - Hepatitis B/C co‑infection: use with caution due to increased risk of hepatic injury. - Pregnancy considerations: evaluate risk‑benefit, as safety data are limited. - Drug resistance: avoid monotherapy to prevent emergence of resistant HIV strains. - Concomitant CYP inducers: avoid strong inducers that may reduce nevirapine levels. - Store at room temperature (below 25°C): keep in the original container, protect from moisture and light.

Nevirapine interacts with several medicines that can alter its effectiveness or safety.

Major Interactions (Avoid): - Rifampicin: strong enzyme inducer that markedly lowers nevirapine plasma concentrations. - St. John’s wort: herbal inducer that reduces drug exposure. - Carbamazepine: CYP3A4 inducer leading to subtherapeutic levels.

Moderate Interactions (Monitor Closely): - Protease inhibitors (e.g., lopinavir/ritonavir): may increase nevirapine levels and risk of toxicity. - Azole antifungals (e.g., ketoconazole): can raise nevirapine concentrations. - Hormonal contraceptives: nevirapine may reduce efficacy, requiring alternative contraception.